Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Sciences of Pharmacy

Ethyl Acetate Fraction of Gynura procumbens Mitigates Hyperglycemia, Dyslipidemia, and Tissue Damage in Streptozotocin-Induced Diabetic Rats Mulyani, Yani; Kaniawati, Marita; Aligita, Widhya; Nugraha, Eka Rahmat
Sciences of Pharmacy Volume 4 Issue 4
Publisher : ETFLIN Publishing House

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58920/sciphar0404371

Abstract

Dyslipidemia is a lipid metabolism disorder frequently associated with diabetes mellitus and known to increase cardiovascular risk. Although Gynura procumbens has been reported to possess antidiabetic and antidyslipidemic properties, studies focusing on the specific effects of its ethyl acetate fraction remain limited. This study investigated the therapeutic potential of the ethyl acetate fraction of ethanol extract from G. procumbens in streptozotocin-induced diabetic rats, particularly its impact on blood glucose, lipid profiles, and histological changes in pancreatic and aortic tissues. Thirty rats were randomly assigned to six groups: normal control, diabetic control, glibenclamide, simvastatin, and extract-treated groups at 100 and 150 mg/kg body weight. After 28 days of treatment, the 150 mg/kg dose significantly reduced blood glucose by 61.3%, total cholesterol by 42.1%, triglycerides by 47.3%, and LDL by 55.0%, while increasing HDL by 6.3% compared to diabetic control (p < 0.05). Histological analysis demonstrated regeneration of pancreatic β-cells and improvement of vascular structure in the aorta. These findings suggest that the ethyl acetate fraction of G. procumbens may serve as a promising natural agent for managing diabetes and dyslipidemia.
Comparative Glycemic Effectiveness of Long- and Rapid-Acting Insulin in Patients with Type 2 Diabetes Mellitus Sutrisno, Entris; Kaniawati, Marita; Maharani, Ilmi Intan; Sodik, Jajang Japar
Sciences of Pharmacy Volume 4 Issue 4
Publisher : ETFLIN Publishing House

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58920/sciphar0404502

Abstract

Insulin therapy is essential for managing type 2 diabetes mellitus (T2DM), particularly in patients who fail to achieve glycemic targets with oral antidiabetic agents. Long-acting insulin is primarily used to control basal glucose levels, while rapid-acting insulin targets postprandial hyperglycemia. However, comparative real-world evidence regarding their effectiveness on glycated hemoglobin (HbA1c) and fasting blood glucose (FBG) remains limited. This study aimed to evaluate and compare the effectiveness of long-acting and rapid-acting insulin in improving HbA1c and FBG levels among patients with T2DM. A retrospective before–and–after observational study was conducted involving 122 T2DM patients treated at the outpatient unit of Majalaya Regional General Hospital between January and December 2024. Patients received either long-acting insulin (e.g., insulin glargine) or rapid-acting insulin (e.g., insulin lispro and insulin aspart) as monotherapy. Changes in HbA1c and FBG before and after therapy were analyzed using paired t-tests or Wilcoxon signed-rank tests. Clinical effectiveness was defined according to American Diabetes Association criteria as a reduction of ≥1% in HbA1c or ≥30 mg/dL in FBG. Insulin therapy significantly reduced HbA1c (−7.77 ± 3.09, p < 0.001) and FBG levels (Z = −5.53, p < 0.001). Based on ADA criteria, 90.3% of patients achieved an effective reduction in HbA1c, while 43.5% achieved an effective reduction in FBG. Insulin lispro and insulin glargine showed the highest HbA1c-based effectiveness (100%), whereas FBG-based effectiveness varied across formulations. Insulin therapy significantly improves long-term and short-term glycemic control in T2DM patients, with insulin lispro and insulin glargine demonstrating the most consistent effectiveness.